Skip to Content

Lanreotide Disease Interactions

There are 7 disease interactions with lanreotide:


Lanreotide (Includes Lanreotide) ↔ Hepatic Impairment

Moderate Potential Hazard, Moderate plausibility

Applies to: Liver Disease

In clinical trials, a reduced clearance of lanreotide was observed in subjects with moderate to severe hepatic impairment. Patients with moderate to severe hepatic impairment should begin treatment with lanreotide 60 mg. Caution should be exercised when using this agent in patients with moderate or severe hepatic impairment for an extended dosing interval.


Lanreotide (Includes Lanreotide) ↔ Renal Impairment

Moderate Potential Hazard, Moderate plausibility

Applies to: Renal Dysfunction

Lanreotide has not been studied in patients with mild, moderate and severe renal failure. It is recommended to start patients with moderate and severe renal impairment at a lower dose as clinically appropriate.


Lanreotide (Includes Lanreotide) ↔ Thyroid Abnormalities

Moderate Potential Hazard, Moderate plausibility

Applies to: Thyroid Disease

Slight decreases in thyroid function have been seen during treatment with lanreotide. Care should be taken when using this agent in patients with thyroid dysfunctions and it is recommended to monitor thyroid function where clinically indicated.


Somatostatin Analogs (Includes Lanreotide) ↔ Adrenal Insufficiency

Moderate Potential Hazard, Moderate plausibility

Applies to: Adrenal Insufficiency

Treatment with somatostatin analogs may suppress the pituitary hormones other than GH/IGF-1. It is recommended to monitor pituitary function prior to initiation of therapy and periodically during treatment, as clinically appropriate. Patients should be monitored for and instructed on the signs and symptoms of adrenal insufficiency during therapy. If adrenal insufficiency is suspected it should be confirmed and treated per standard of care with exogenous glucocorticoids at replacement doses.


Somatostatin Analogs (Includes Lanreotide) ↔ Bradycardia

Moderate Potential Hazard, Moderate plausibility

Applies to: Heart Disease, Hypothyroidism

Bradycardia has been reported with the use of somatostatin analogs. It is recommended to carefully monitor patients with cardiac disorders for the development of bradycardia. Dose adjustments of beta-blockers, calcium channel blockers, or correction of electrolyte disturbances may be necessary. Care should be taken when initiating treatment with these agents in patients with bradycardia.


Somatostatin Analogs (Includes Lanreotide) ↔ Cholelithiasis

Moderate Potential Hazard, Moderate plausibility

Applies to: Gallbladder Disease

Somatostatin analogs may reduce gallbladder motility and lead to gallstones formation. It is recommended to assess the gallbladder prior to starting therapy and periodically thereafter.


Somatostatin Analogs (Includes Lanreotide) ↔ Diabetes

Moderate Potential Hazard, Moderate plausibility

Applies to: Diabetes Mellitus

Elevations in blood glucose levels have been reported with the use of somatostatin analogs. Cushing's disease patients with poor glycemic control may be at a higher risk of developing severe hyperglycemia and associated complications, e.g., ketoacidosis. It is recommended to assess the glycemic status of hemoglobin A1C prior to starting treatment with these agents. Self-monitoring of blood glucose and/or FPG assessments should be done every week for the first two to three months and periodically thereafter, as clinically appropriate, as well as over the first two to four weeks after any dose increase. If uncontrolled hyperglycemia persists, despite appropriate medical management, the dose of these agents should be reduced or discontinued.

lanreotide drug Interactions

There are 165 drug interactions with lanreotide

lanreotide alcohol/food Interactions

There is 1 alcohol/food interaction with lanreotide

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2018 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.